

2022-10

Traboulsi syndrome caused by mutations in ASPH: An autosomal recessive disorder with overlapping features of Marfan syndrome

Jones, G

<http://hdl.handle.net/10026.1/19758>

10.1016/j.ejmg.2022.104572

European Journal of Medical Genetics

Elsevier

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

1 **Traboulsi syndrome caused by mutations in *ASPH*: An autosomal recessive**
2 **disorder with overlapping features of Marfan syndrome**

3 Gabriela Jones^{a1}, Katie Johnson^{a1}, Jacqueline Eason^a, Mark Hamilton^{a2}, Deborah
4 Osio^b, Farah Kanani^b, Julia Baptista^{cd3}, Mohnish Suri^a

5 a-Clinical Genetics Department, Nottingham University Hospitals NHS Trust,
6 Nottingham, UK

7 b-Clinical Genetics Department, Birmingham Women's Hospital, Birmingham, UK

8 c-Exeter Molecular Genetics Laboratory, Exeter, UK

9 d-Peninsula Medical School, Faculty of Health, University of Plymouth, UK

10

11 **Abstract**

12 Traboulsi syndrome, otherwise known as facial dysmorphism, lens dislocation,
13 anterior-segment abnormalities and spontaneous filtering blebs, is an autosomal
14 recessive condition associated with characteristic ocular features including dislocated
15 crystalline lenses, anterior segment abnormalities and in some individuals, non-
16 traumatic conjunctival cysts. There is a distinctive facial appearance which includes
17 flattened malar region with convex nasal ridge. Alterations in the aspartate beta-
18 hydroxylase (*ASPH*) gene are known to be the cause of the condition.

19 We report seven further individuals from six unrelated families with characteristic
20 ocular and facial features. Five individuals had aortic root dilatation, with childhood
21 onset in some, and one undergoing aortic root repair aged 47 years for severe aortic
22 regurgitation and aortic root dilatation. Interestingly, inguinal hernias were commonly
23 reported. Although some skeletal features were seen, these were not consistent. One
24 of the patients had mild deficiency of factor VII on clotting studies. The *ASPH* protein
25 hydroxylates specific asparagine- and aspartate-residues in epidermal growth
26 factor (EGF)-domain containing proteins including coagulation factors and associated
27 genes including *FBN1*. We propose this as an explanation for the overlap in clinical

28 features with Marfan syndrome and conclude that Traboulsi syndrome is an important
29 differential diagnosis. We strongly recommend echocardiography surveillance for
30 patients with Traboulsi syndrome.

31

32 **Introduction**

33 Traboulsi syndrome, otherwise known as facial dysmorphism, lens dislocation,
34 anterior-segment abnormalities and spontaneous filtering blebs (MIM: [601522](#)) is a
35 rare genetic condition for which the genetic basis was described in 2014 (Patel et al.,
36 2014). Until now, there have been limited cases reported in the literature. The
37 condition was originally reported in a multiply consanguineous family from the Druze
38 sect in Lebanon in 1995 (Shawaf et al., 1995). All affected individuals had ectopia
39 lentis and facial dysmorphism. Progressive scleral thinning with spontaneous filtering
40 blebs, peripheral irido-corneal adhesions, and glaucoma were also seen. Four
41 individuals from an unrelated family from the same ethnic background were
42 subsequently also reported. The family history was highly suggestive of an autosomal
43 recessive inheritance pattern for this condition (Haddad et al., 2001). All affected
44 individuals had lens dislocation, cataracts ± anterior chamber anomalies and a
45 distinctive facial appearance with a convex nasal ridge, long face and dental crowding.
46 Mansour et al. (2013) reported a 16 year old girl with similar features.

47 In 2014, Patel et al., confirmed the genetic basis for Traboulsi syndrome Patel et al.
48 (2014). They identified two different homozygous mutations in the aspartate-β-
49 hydroxylase gene (*ASPH*) in three families. Two of the families had been reported
50 previously and carried the same mutation (Mansour et al., 2013; Haddad et al., 2001).
51 They confirmed that *ASPH* is strongly expressed in the snout, limbs and eye (in
52 particular the developing lens) of mouse embryos, which would provide an explanation
53 for the clinical features associated with this condition. Since then further patients have
54 been identified incidentally through exome sequencing studies in consanguineous
55 families with congenital anomalies of the kidneys and urinary tract in a patient with
56 lens dislocation and vesico-ureteric reflux (VUR) (Vivante et al., 2017), and through
57 ophthalmic clinics (Siggs et al., 2019; Chandran et al., 2019; Kulkarni et al., 2019;
58 Shanmugam et al., 2020; Van Hoorde et al., 2021; Senthil et al., 2021). These patients
59 presented with characteristic facial and ocular features. These reports mainly focussed
60 on the ocular phenotype and management. However, it is interesting to note that two
61 of the patients reported by Senthil et al. (2021) had additional cardiac findings
62 including one with mitral valve prolapse and mild mitral regurgitation and one with

63 severe aortic regurgitation requiring surgery that subsequently died of problems
64 related to this. A 34 year old male was also reported by Lei et al. 2020. He had been
65 previously diagnosed with Marfan syndrome in view of tall stature, thin body habitus
66 and bilateral ectopia lentis. He presented to the respiratory clinic with lung bullae,
67 recurrent left-sided spontaneous pneumothorax and was also found to have a
68 ventricular septal defect. A molecular diagnosis of Traboulsi syndrome was later
69 confirmed, and the authors questioned whether the additional features could be
70 related to this diagnosis.

71 Herein, we report seven further individuals from six apparently unrelated families
72 identified through genetics clinics with confirmed molecular diagnoses and features
73 consistent with Traboulsi syndrome. These patients exhibited additional cardiac,
74 musculoskeletal and haematological features thus expanding the phenotypic
75 spectrum of Traboulsi syndrome and demonstrating considerable overlap with Marfan
76 syndrome.

77 **Section snippets**

78 **Patient selection and methods**

79 All patients were referred to their regional clinical genetics service with ectopia lentis
80 or anterior chamber anomalies, for investigation of an underlying syndromic genetic
81 cause. Patient 1 was investigated by exome sequencing as part of the DDD study
82 (Firth and Wright 2011) using the molecular methods and bioinformatics pipeline for
83 exome analysis previously described (Wright et al., 2015). Confirmation of
84 the *ASPH* variant was done using Sanger sequencing (Fig. 1B). Patients 2 & 3 had

85 **Clinical findings**

86 Fig. 1 shows the pedigrees of the 7 patients and their phenotypic data are summarized
87 in Table 1, with further detailed clinical information provided as online supplementary
88 file 1. The parents of 6 of the 7 patients were consanguineous and two patients had
89 relatives with a similar phenotype, whose parents were also consanguineous. All of
90 the patients presented initially with ocular features. This ranged from the incidental
91 finding of lens dislocation in patient 4 whilst wishing to undergo

92 **Discussion**

93 Traboulsi syndrome is a rare autosomal recessive disorder with a primary eye
94 phenotype of ectopia lentis, shallow anterior chambers with variable degree of angle
95 closure by iridocorneal adhesions, patchy iris atrophy and spontaneous filtering
96 conjunctival blebs, associated with facial dysmorphism (Shawaf S et al. Ophthalmic

97 Genet 1995; Haddad R et al. Am J Med Genet 2001; Mansour AM et al. Case Rep
98 Ophthalmol 2013). The typical dysmorphic facial features of Traboulsi syndrome
99 include

100 **CRedit authorship contribution statement**

101 **Gabriela Jones:** Conceptualization, Writing – original draft, Data curation, Writing –
102 review & editing, Funding acquisition. **Katie Johnson:** Writing – original draft, Data
103 curation, Writing – review & editing, Funding acquisition. **Jacqueline Eason:** Writing
104 – review & editing, Funding acquisition. **Mark Hamilton:** Writing – review & editing,
105 Funding acquisition. **Deborah Osio:** Writing – review & editing. **Farah**
106 **Kanani:** Writing – review & editing, Funding acquisition. **Julia Baptista:** Methodology

107

108 **Declaration of competing interest**

109 The authors have no conflicts of interest to declare.

110

111 **Acknowledgements**

112 The authors would like to thank the families for agreeing to the publication of clinical
113 details and photographs. The authors would also like to acknowledge the Deciphering
114 Developmental Disorders study. The DDD study presents independent research
115 commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-
116 003]. This study makes use of DECIPHER (<http://www.deciphergenomics.org>), which
117 is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html
118 for full acknowledgement.

119

120 **References**

121 Hugo H Abarca Barriga, Nathaly Caballero, Milana Trubnykova, Maria Del Carmen
122 Castro-Mujica, Jorge E La Serna-Infantes, Flor Vasquez, Raoul C Hennekam. **A**
123 **novel ASPH variant extends the phenotype of Shawaf-Traboulsi syndrome.** Am.
124 J. Med. Genet. A, 11 (2018), pp. 2494-2500

125 P. Chandran, P. Chermakani, P. Venkataraman, S.P. Thilagar, G.V. Raman. **A novel**
126 **5 bp homozygous deletion mutation in ASPH gene associates with Traboulsi**
127 **syndrome.** Ophthalmic Genet., 40 (2019), pp. 185-187

128 J.E. Dinchuk, R.J. Focht, J.A. Kelley, N.L. Henderson, N.I. Zolotarjova, R. Wynn, N.T.
129 . Neff, J. Link, R.M. Huber, T.C. Burn, M.J. Rupa, M.R. Cunningham, B.H. Selling, J.
130 Ma, A.A. Stern, G.F. Hollis, R.B. Stein, P.A. Friedman **Absence of post-**
131 **translational aspartyl beta-hydroxylation of epidermal growth factor domains in**
132 **mice leads to developmental defects and an increased incidence of intestinal**
133 **neoplasia.** J. Biol. Chem., 277 (2002), pp. 12970-12977

134 H.V. Firth, C.F. Wright, DDD Study. **The deciphering developmental disorders**
135 **(DDD) study.** Dev. Med. Child Neurol., 53 (2011), pp. 702-703

136 R. Haddad, S. Uwuydat, R. Dakroub, E.I. Traboulsi. **Confirmation of the autosomal**
137 **recessive syndrome of ectopia lentis and distinctive craniofacial appearance.**
138 Am. J. Med. Genet., 99 (2001), pp. 185-189

139 Browser, W.J. Kent, C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler
140 , D. Haussler. **The human genome browser at UCSC.** Genome Res., 12 (2002),
141 pp. 996-1006

142 N. Kulkarni, I.C. Lloyd, J. Ashworth, S. Biswas, G.C.M. Black, N.I.H.R. BioResource
143 Consortium, J. Clayton-Smith. **Traboulsi syndrome due to ASPH mutation: an**
144 **under-recognised cause of ectopia lentis.** Clin. Dysmorphol., 28 (2019), pp. 184-
145 189

146 C. Lei, T. Guo, S. Ding, L. Liao, H. Peng, Z. Tan, H. Luo. **Whole-exome sequencing**
147 **identified a novel homozygous ASPH frameshift variant causing Traboulsi**
148 **syndrome in a Chinese family.** Mol. Genet. Genomic Med., 9 (2020), p. e1553

149 B.L. Loeys, H.C. Dietz, A.C. Braverman, B.L. Callewert, J. De
150 Backer, R.B. Devereux, Y. Hilhorst-
151 Hofstee, G. Jondeau, L. Faivre, D.M. Milewicz, R.E. Pyeritz, P.D. Sponseller, P. Wor
152 dsworth, A.M. De Paepe. **The revised Ghent nosology for Marfan syndrome.** J.
153 Med. Genet., 47 (2010), pp. 476-485

154 A.M. Mansour, M.H. Younis, R.H. Dakroub. **Anterior segment imaging and**
155 **treatment of a case with syndrome of ectopia lentis, spontaneous filtering blebs,**
156 **and craniofacial dysmorphism.** Case Rep. Ophthalmol., 4 (2013), pp. 84-90

157 N. Patel, A.O. Khan, A. Mansour, J.Y. Mohamed, A. Al
158 Assiri, R. Haddad, X. Jia, Y. Xiong, A. Megarbane, E.I. Traboulsi, F.S. Alkuraya.
159 **Mutations in ASPH cause facial dysmorphism, lens dislocation, anterior-**
160 **segment abnormalities, and spontaneous filtering blebs, or Traboulsi**
161 **syndrome.** Am. J. Hum. Genet., 94 (2014), pp. 755-759

162 I. Pfeffer, L. Brewitz, T. Krojer, S.A. Jensen, G.T. Kochan, N.J. Kershaw, L.A. Hewits
163 on Ks<
164 McNeill, H. Kramer, M. Munzel, R.J. Hopkinson, U. Oppermann, P.A. Handford, M.A.
165 DcDonough, C.J. Schofield. **Aspartate/asparagine-β-hydroxylase crystal**

166 **structures reveal an unexpected epidermal growth factor-like domain substrate**
167 **disulfide pattern.** Nat. Commun., 28 (2019), p. 4901

168 S. Senthil, S. Sharma, S. Vishwakarma, I. Kaur. **A novel mutation in the aspartate**
169 **beta-hydroxylase (ASPH) gene is associated with a rare form of Traboulsi**
170 **syndrome.** Ophthalmic Genet., 42 (2021), pp. 28-34

171 P.M. Shanmugam, P. Sagar, V.K. Konana, S. Simakurthy, R. Ramanjulu, A. Sheema
172 r, K.C.D. Mishra. **Recurrent unintentional filtering blebs after vitrectomy.** Indian J.
173 Ophthalmol., 68 (2020), pp. 660-662

174 S. Shawaf, B. Nouredin, A. Khouri, E. Traboulsi. **A family with a syndrome of**
175 **ectopia lentis, spontaneous filtering blebs, and craniofacial dysmorphism.**
176 Ophthalmic Genet., 16 (1995), pp. 163-169

177 O. Siggs, E. Souzeau, J.E. Craig. **Loss of ciliary zonule protein hydroxylation and**
178 **lens stability as a predicted consequence of biallelic ASPH variation.** Ophthalmic
179 Genet., 40 (2019), pp. 12-16

180 T. Van Hoorde, F. Nerinckx, E. Kreps, D. Roels, P. Huyghe, M. Van
181 Heetvelde, H. Verdin, E. De Baere, I. Balikova, B.P. Leroy. **Expanding the clinical**
182 **spectrum and management of Traboulsi syndrome: report on two siblings**
183 **homozygous for a novel pathogenic variant in ASPH.**Ophthalmic
184 Genet., 42 (2021), pp. 493-499

185 A. Vivante, D.-Y. Hwang, S. Kuhl, J. Chen, S. Shril, J. Schulz, A. van der
186 Ven, G. Daouk, N.A. Soliman, A.S. Kumar, P. Senguttuvan, E.O. Kehinde, V. Tasic,
187 F. Hildebrandt. **Exome sequencing discerns syndromes in patients from**
188 **consanguineous families with congenital anomalies of the kidneys and urinary**
189 **tract.** J. Am. Soc. Nephrol., 27 (2017), pp. 69-75

190 C.F. Wright, T.W. Fitzgerald, W.D. Jones, S. Clayton, J.F. McRae, M. van
191 Kogelenberg, D.A. King, K. Ambridge, D.M. Barrett, T. Bayzetinova, A.P. Bevan, E.
192 Bragin, E.A. Chatzimichali, S. Gribble, P. Jones, N. Krishnappa, L.E. Mason, R. Mille
193 r, K.I. Morley, V. Parthiban, E. Prigmore, D. Rajan, A. Sifrim, G.J. Swaminathan, A.R.
194 Tivey, A. Middleton, M. Parker, N.P. Carter, J.C. Barrett, M.E. Hurles, D.R. FitzPatri
195 ck, H.V. Firth, DDD study. **Genetic diagnosis of developmental disorders in the**
196 **DDD study: a scalable analysis of genome-wide research data**
197 Lancet, 385 (2015), pp. 1305-1314